AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17855282 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention modelled on the WHO/UNICEF baby friendly hospital initiative
Number of subjects: 17046
Study 17855282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 17046
Study 15239141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 0.2 g/kg body weight daily + Soybean oil (SO) 0.8 g/kg body weight daily (n = 24)
Number of subjects: 44
Study 15239141 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) 1.0 g/kg body weight daily (n = 20)
Number of subjects: 44
Study 15239141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) treatment
Number of subjects: 44
Study 11514082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional patients
Number of subjects: 0
Study 11514082 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonally distressed patients
Number of subjects: 0
Study 11514082 — intervention group
Group type: COMPARATOR
Intervention: Adaptive copers
Number of subjects: 0
Study 11514082 — intervention group
Group type: EXPERIMENTAL
Intervention: All subgroups
Number of subjects: 0
Study 9591521 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 298
Study 9591521 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 298
Study 9591521 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 298
Study 7887018 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus killed promastigotes (group A)
Number of subjects: 208
Study 7887018 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alone (group B)
Number of subjects: 208
Study 7887018 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed promastigotes alone (group C)
Number of subjects: 208
Study 7887018 — intervention group
Group type: COMPARATOR
Intervention: Diluents control (placebo, group D)
Number of subjects: 208
Study 2974781 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin by means of a pen injector (Insuject‐X)
Number of subjects: 50
Study 2974781 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringes
Number of subjects: 50
Study 31267292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (mean dose 11.8 mg/day)
Number of subjects: 158
Study 31267292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 31267292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 158
Study 30379222 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group with 8h of intensive treatment to maximize oxygen delivery
Number of subjects: 99
Study 30379222 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 99
Study 30379222 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group
Number of subjects: 99
Study 30379222 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 30379222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 27460471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health optimized diet (low in carbohydrates, rich in Omega‐3 fatty acids, vitamins C and D, antioxidants, and fiber) for four weeks
Number of subjects: 15
Study 27460471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary change)
Number of subjects: 15
Study 25673173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior hypogastric plexus blockade
Number of subjects: 117
Study 25673173 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 117
Study 23312487 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone vaginal gel 4% (1g/day)
Number of subjects: 90
Study 23312487 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen cream (0.3mg/day)
Number of subjects: 90
Study 23312487 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 20492051 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60
Study 20492051 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 18276723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physical therapy plus standard treatment for pneumonia
Number of subjects: 98
Study 18276723 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for pneumonia alone
Number of subjects: 98
Study 17065118 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 40
Study 17065118 — intervention group
Group type: COMPARATOR
Intervention: Sutter implants
Number of subjects: 40
Study 17065118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 12967810 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser iridotomy (Ar-LI group)
Number of subjects: 23
Study 12967810 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon combined with YAG laser iridotomy (Ar-YAG-LI group)
Number of subjects: 23
Study 12967810 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 10687884 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 876
Study 10687884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study 9324343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBSC support (Regimen A: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 5 g/m2, thiotepa 300 mg/m2; Regimen A': carmustine 600 mg/m2 replacing cyclophosphamide; Regimen B: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 7 g/m2, thiotepa 900 mg/m2)
Number of subjects: 10
Study 1437030 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat occlusal splint
Number of subjects: 51
Study 1437030 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 51
Study 3549397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Biken) containing F-HA and pertussis toxin toxoid; specific dosage and duration not mentioned.
Number of subjects: 0
Study 3549397 — intervention group
Group type: COMPARATOR
Intervention: Plain whole cell vaccine; specific dosage and duration not mentioned.
Number of subjects: 0
Study 3549397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Biken) with aluminium phosphate as adjuvant; specific dosage and duration not mentioned.
Number of subjects: 0
Study 31295174 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral treatment (ART) regimen
Number of subjects: 3333
Study 31295174 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 3333
Study 31295174 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 3333
Study 31295174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ART regimens (protease inhibitor-based and ZDV)
Number of subjects: 3333
Study 31295174 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 3333
Study 29480886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based video exercise
Number of subjects: 125
Study 29480886 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (educational pamphlet)
Number of subjects: 125
Study 26342472 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 months of dual antiplatelet therapy (DAPT)
Number of subjects: 1754
Study 26342472 — intervention group
Group type: COMPARATOR
Intervention: 6 months of dual antiplatelet therapy (DAPT)
Number of subjects: 1754
Study 24712378 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d yellow pea fibre
Number of subjects: 30
Study 24712378 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 30
Study 22668852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern intervention (3 dietary patterns)
Number of subjects: 206
Study 20598833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (NP)
Number of subjects: 424
Study 20598833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study 20598833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NP and placebo)
Number of subjects: 424
Study 17569128 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine, interferon alpha (IFN‐alpha 2b), or sequential therapy with lamivudine-IFN‐alpha 2b for 48 weeks
Number of subjects: 71
Study 15305694 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Active AntiRetroviral Therapy (HAART)
Number of subjects: 0
Study 15305694 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study 11583526 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-s standard
Number of subjects: 3
Study 11583526 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-s standard
Number of subjects: 3
Study 9794107 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the codon 354 variant (GIP receptor variant)
Number of subjects: 451
Study 9794107 — intervention group
Group type: COMPARATOR
Intervention: Wild-type receptor
Number of subjects: 451
Study 7641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.02 mg.kg‐1.h‐1
Number of subjects: 410
Study 7641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.25 mg.kg‐1.h‐1
Number of subjects: 410
Study 7641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.5 mg.kg‐1.h‐1
Number of subjects: 410
Study 7641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg.kg‐1.h‐1
Number of subjects: 410
Study 7641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog (all doses)
Number of subjects: 410
Study 7641350 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 410
Study 2619334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined wooden spatula and cytobrush
Number of subjects: 75
Study 2619334 — intervention group
Group type: COMPARATOR
Intervention: Combined wooden spatula and cotton swab
Number of subjects: 75
Study 319815 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 80 mg i.v.
Number of subjects: 100
Study 319815 — intervention group
Group type: COMPARATOR
Intervention: Control (no doxapram)
Number of subjects: 100
Study 29505434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tresident (polyvinylsiloxane)
Number of subjects: 20
Study 29505434 — intervention group
Group type: COMPARATOR
Intervention: Orthoprint (irreversible hydrocolloid)
Number of subjects: 20
Study 28332025 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric 'Live High-Train Low' (LHTL) for 6 weeks at altitudes of 2500-3500 m
Number of subjects: 7
Study 28332025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normoxia) for 6 weeks
Number of subjects: 7
Study 28332025 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric 'Live High-Train Low' (LHTL) for 6 weeks
Number of subjects: 7
Study 25171883 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of triamcinolone at the borders of the wall lacerations during each dilation session
Number of subjects: 19
Study 25171883 — intervention group
Group type: COMPARATOR
Intervention: Dilation alone (control)
Number of subjects: 19
Study 23305566 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Group - 30 mg elemental iron weekly for 10 months (40 doses)
Number of subjects: 99
Study 23305566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical Group - 30 mg elemental iron daily for 20 days, two cycles separated by four months (40 doses total)
Number of subjects: 99
Study 23305566 — intervention group
Group type: COMPARATOR
Intervention: Control Group - Not applicable
Number of subjects: 99
Study 21161264 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (B) with bicarbonate
Number of subjects: 11
Study 21161264 — intervention group
Group type: COMPARATOR
Intervention: HIT (P) with placebo
Number of subjects: 11
Study 21161264 — intervention group
Group type: COMPARATOR
Intervention: HVT (high-volume endurance training)
Number of subjects: 11
Study 19109444 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT + FST
Number of subjects: 30
Study 19109444 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 30
Study 19109444 — intervention group
Group type: COMPARATOR
Intervention: CPT + CPT
Number of subjects: 30
Study 17954153 — intervention group
Group type: EXPERIMENTAL
Intervention: Taguchi technique
Number of subjects: 277
Study 17954153 — intervention group
Group type: COMPARATOR
Intervention: Lich-Gregoir technique
Number of subjects: 277
Study 16078092 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 60
Study 16078092 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 11823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical and imaging information (NIH Stroke Scale + CT infarct volume)
Number of subjects: 201
Study 11823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical information alone (NIH Stroke Scale)
Number of subjects: 201
Study 11823654 — intervention group
Group type: COMPARATOR
Intervention: Imaging information alone (CT infarct volume)
Number of subjects: 201
Study 10346551 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 10346551 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 7720760 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sublingual ISDN
Number of subjects: 24
Study 7720760 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-kcal, 300-ml mixed liquid meal
Number of subjects: 24
Study 7720760 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sublingual ISDN followed by meal
Number of subjects: 24
Study 7720760 — intervention group
Group type: EXPERIMENTAL
Intervention: meal followed by 5 mg sublingual ISDN
Number of subjects: 24
Study 2188182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus insulin (20 units NPH and 10 units regular)
Number of subjects: 108
Study 2188182 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 108
Study 7434206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerium nitrate-silver sulfadiazine cream
Number of subjects: 60
Study 7434206 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 60
Study 30260366 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 43
Study 27664457 — intervention group
Group type: EXPERIMENTAL
Intervention: Wormwood tea (bitter group; n = 20)
Number of subjects: 39
Study 27664457 — intervention group
Group type: COMPARATOR
Intervention: Water (control group; n = 19)
Number of subjects: 39
Study 25876430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser irradiation (HILl)
Number of subjects: 40
Study 25876430 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 24481893 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation
Number of subjects: 289
Study 24481893 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group demonstration
Number of subjects: 289
Study 24481893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed slide show
Number of subjects: 289
Study 21880242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30/45 mg)
Number of subjects: 149
Study 21880242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pioglitazone and Ramipril (PIRA)
Number of subjects: 149
Study 21880242 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (2.5/5 mg)
Number of subjects: 149
Study 21880242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 149
Study 21880242 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 149
Study 19662998 — intervention group
Group type: EXPERIMENTAL
Intervention: BJVC
Number of subjects: 16
Study 19662998 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 17536872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin (TSI) 300mg/4mL
Number of subjects: 247
Study 17536872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 14996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative imprint cytology of sentinel nodes
Number of subjects: 400
Study 14996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate axillary clearance
Number of subjects: 400
Study 14996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed axillary clearance
Number of subjects: 400
Study 14996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node involvement
Number of subjects: 400
Study 14996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful identification of sentinel node
Number of subjects: 400
Study 9868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 200
Study 9868668 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ lymphocyte proportion at baseline > 66%
Number of subjects: 200
Study 9868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in CD8+ lymphocyte proportion at month 1 > 5%
Number of subjects: 200
Study 8032706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 56
Study 8032706 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 56
Study 2588918 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatula-Cytobrush method
Number of subjects: 0
Study 2588918 — intervention group
Group type: COMPARATOR
Intervention: Spatula-cotton swab method
Number of subjects: 0
Study 55586 — intervention group
Group type: EXPERIMENTAL
Intervention: Three biscuits daily each containing 10 g of ordinary miller's bran
Number of subjects: 59
Study 55586 — intervention group
Group type: COMPARATOR
Intervention: Wheat biscuits of a similar appearance (control group)
Number of subjects: 59
Study 31153976 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT guidelines
Number of subjects: 1000
Study 31153976 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT extensions
Number of subjects: 1000
Study 29224298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual smoking cessation
Number of subjects: 314
Study 29224298 — intervention group
Group type: COMPARATOR
Intervention: Abrupt smoking cessation
Number of subjects: 314
Study 25027443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed treadmill training (n = 30)
Number of subjects: 61
Study 25027443 — intervention group
Group type: COMPARATOR
Intervention: Progressive treadmill training (n = 31)
Number of subjects: 61
Study 21672343 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 90
Study 21672343 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 90
Study 18600436 — intervention group
Group type: EXPERIMENTAL
Intervention: Biased instructions and positive feedback
Number of subjects: 0
Study 18600436 — intervention group
Group type: EXPERIMENTAL
Intervention: Biased instructions
Number of subjects: 0
Study 18600436 — intervention group
Group type: COMPARATOR
Intervention: No pre-identification feedback
Number of subjects: 0
Study 18600436 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pre-identification feedback
Number of subjects: 0
Study 18600436 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pre-identification feedback
Number of subjects: 0
Study 16308544 — intervention group
Group type: EXPERIMENTAL
Intervention: DCBT4567‐Astha‐15
Number of subjects: 94
Study 16308544 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day)
Number of subjects: 94
Study 16308544 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day) + Theophylline (200 mg/day)
Number of subjects: 94
Study 16308544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 15617457 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 58
Study 15617457 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 58
Study 11500251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (25, 50, 100 mg im)
Number of subjects: 18
Study 11500251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg im)
Number of subjects: 18
Study 11500251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9257071 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ratio Estimate (MRE) statistic applied to analyze data of vein grafts
Number of subjects: 0
Study 9257071 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ratio Estimate (MRE) statistic
Number of subjects: 0
Study 8342904 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 0.6 mg/kg/day for 2 weeks
Number of subjects: 18
Study 3098340 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation (lumpectomy followed by radiotherapy)
Number of subjects: 101
Study 3098340 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 101
Study 29246847 — intervention group
Group type: EXPERIMENTAL
Intervention: medical care
Number of subjects: 50
Study 29246847 — intervention group
Group type: EXPERIMENTAL
Intervention: community‐based group exercise
Number of subjects: 50
Study 29246847 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic‐based manual therapy and individualized exercise
Number of subjects: 50
Study 27575024 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 400
Study 27575024 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 400
Study 25050337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom (BV) ointment applied locally over masseter muscles for 14 days during a 3-minute massage.
Number of subjects: 0
Study 25050337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaseline) applied during a 3-minute massage.
Number of subjects: 0
Study 25050337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom (BV) ointment
Number of subjects: 0
Study 25050337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaseline)
Number of subjects: 0
Study 25050337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0005% BV ointment
Number of subjects: 0